Aaron Michels
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 73 | 2026 | 3937 | 7.620 |
Why?
| | Receptors, Antigen, T-Cell | 16 | 2025 | 673 | 3.440 |
Why?
| | Islets of Langerhans | 19 | 2026 | 847 | 3.210 |
Why?
| | Autoantigens | 17 | 2025 | 427 | 3.180 |
Why?
| | Autoantibodies | 24 | 2026 | 1509 | 3.070 |
Why?
| | Insulin | 31 | 2026 | 2516 | 2.980 |
Why?
| | T-Lymphocytes | 13 | 2025 | 1997 | 1.830 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2022 | 198 | 1.800 |
Why?
| | Insulin-Secreting Cells | 10 | 2025 | 392 | 1.590 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2019 | 266 | 1.560 |
Why?
| | HLA Antigens | 4 | 2025 | 240 | 1.450 |
Why?
| | Autoimmunity | 15 | 2025 | 933 | 1.450 |
Why?
| | CD4-Positive T-Lymphocytes | 15 | 2025 | 1146 | 1.400 |
Why?
| | Hypoglycemic Agents | 10 | 2026 | 1399 | 1.380 |
Why?
| | Immunotherapy | 8 | 2025 | 667 | 1.320 |
Why?
| | Insulin Antibodies | 5 | 2026 | 103 | 1.300 |
Why?
| | Antibodies, Monoclonal | 5 | 2020 | 1505 | 1.180 |
Why?
| | Peptides | 7 | 2026 | 998 | 1.180 |
Why?
| | Autoimmune Diseases | 5 | 2019 | 469 | 1.050 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2018 | 364 | 0.980 |
Why?
| | HLA-DQ Antigens | 7 | 2019 | 174 | 0.960 |
Why?
| | Immunologic Factors | 3 | 2019 | 260 | 0.910 |
Why?
| | HLA-DR Antigens | 3 | 2022 | 220 | 0.890 |
Why?
| | Antigen Presentation | 2 | 2018 | 208 | 0.810 |
Why?
| | Melanoma | 2 | 2022 | 761 | 0.810 |
Why?
| | Protein Precursors | 3 | 2021 | 136 | 0.790 |
Why?
| | Peptide Fragments | 7 | 2026 | 696 | 0.770 |
Why?
| | Humans | 83 | 2026 | 145763 | 0.760 |
Why?
| | Models, Immunological | 2 | 2015 | 99 | 0.730 |
Why?
| | Cell Cycle Checkpoints | 2 | 2020 | 97 | 0.730 |
Why?
| | B7-H1 Antigen | 3 | 2021 | 244 | 0.730 |
Why?
| | Methyldopa | 2 | 2019 | 6 | 0.700 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2025 | 54 | 0.640 |
Why?
| | HLA-DQ beta-Chains | 1 | 2020 | 58 | 0.630 |
Why?
| | Child | 32 | 2026 | 22739 | 0.610 |
Why?
| | Disease Susceptibility | 1 | 2021 | 344 | 0.610 |
Why?
| | Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.610 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.600 |
Why?
| | Health Fairs | 1 | 2019 | 10 | 0.600 |
Why?
| | Stevens-Johnson Syndrome | 2 | 2019 | 37 | 0.590 |
Why?
| | Antigens | 4 | 2018 | 348 | 0.590 |
Why?
| | Adolescent | 29 | 2026 | 22573 | 0.550 |
Why?
| | Preventive Medicine | 1 | 2018 | 39 | 0.540 |
Why?
| | Proinsulin | 2 | 2017 | 54 | 0.520 |
Why?
| | Mice, Inbred NOD | 10 | 2026 | 616 | 0.520 |
Why?
| | Epitopes | 5 | 2025 | 473 | 0.510 |
Why?
| | Alleles | 5 | 2022 | 896 | 0.510 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 210 | 0.510 |
Why?
| | Antibody Formation | 1 | 2018 | 288 | 0.490 |
Why?
| | Influenza, Human | 1 | 2022 | 624 | 0.480 |
Why?
| | Immunity, Cellular | 1 | 2018 | 274 | 0.480 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2399 | 0.460 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 126 | 0.450 |
Why?
| | Young Adult | 19 | 2026 | 14251 | 0.450 |
Why?
| | Major Histocompatibility Complex | 2 | 2013 | 233 | 0.440 |
Why?
| | Rituximab | 1 | 2016 | 210 | 0.430 |
Why?
| | Graft Rejection | 1 | 2018 | 521 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2026 | 992 | 0.420 |
Why?
| | HLA-D Antigens | 1 | 2014 | 30 | 0.420 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1133 | 0.420 |
Why?
| | Diet Therapy | 1 | 2014 | 36 | 0.420 |
Why?
| | Hypoglycemia | 3 | 2016 | 480 | 0.410 |
Why?
| | Drug Hypersensitivity | 1 | 2015 | 90 | 0.410 |
Why?
| | Addison Disease | 1 | 2014 | 38 | 0.410 |
Why?
| | Adrenal Glands | 1 | 2014 | 76 | 0.400 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 981 | 0.400 |
Why?
| | Biomarkers | 4 | 2025 | 4302 | 0.400 |
Why?
| | Age of Onset | 2 | 2026 | 557 | 0.400 |
Why?
| | Female | 42 | 2026 | 79035 | 0.400 |
Why?
| | Antibodies | 1 | 2015 | 397 | 0.390 |
Why?
| | Male | 38 | 2026 | 73003 | 0.390 |
Why?
| | Blood Glucose | 5 | 2026 | 2344 | 0.380 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 107 | 0.380 |
Why?
| | Child, Preschool | 16 | 2026 | 11868 | 0.370 |
Why?
| | Disease Progression | 6 | 2021 | 2865 | 0.370 |
Why?
| | Prediabetic State | 1 | 2015 | 250 | 0.360 |
Why?
| | Mass Screening | 3 | 2019 | 1361 | 0.360 |
Why?
| | Infant | 11 | 2026 | 10090 | 0.330 |
Why?
| | Animals | 24 | 2026 | 38097 | 0.330 |
Why?
| | C-Peptide | 6 | 2026 | 190 | 0.330 |
Why?
| | Adult | 30 | 2026 | 40872 | 0.330 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 84 | 0.330 |
Why?
| | Glycine | 1 | 2011 | 186 | 0.320 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.320 |
Why?
| | Struma Ovarii | 1 | 2010 | 8 | 0.310 |
Why?
| | Macromolecular Substances | 1 | 2010 | 216 | 0.310 |
Why?
| | Endocrine System Diseases | 1 | 2010 | 35 | 0.300 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 838 | 0.300 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 334 | 0.290 |
Why?
| | Middle Aged | 21 | 2026 | 36302 | 0.270 |
Why?
| | Transcription Factor 7-Like 2 Protein | 2 | 2018 | 26 | 0.270 |
Why?
| | Haplotypes | 3 | 2020 | 500 | 0.270 |
Why?
| | Zinc Transporter 8 | 2 | 2026 | 70 | 0.270 |
Why?
| | Carbamazepine | 2 | 2019 | 24 | 0.260 |
Why?
| | Glutamate Decarboxylase | 4 | 2017 | 165 | 0.250 |
Why?
| | Inflammation | 2 | 2017 | 2883 | 0.250 |
Why?
| | Pediatrics | 1 | 2015 | 1125 | 0.250 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2020 | 2602 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2021 | 923 | 0.240 |
Why?
| | Neoplasms | 2 | 2020 | 2913 | 0.240 |
Why?
| | Mice | 14 | 2026 | 18355 | 0.230 |
Why?
| | Antilymphocyte Serum | 2 | 2016 | 57 | 0.230 |
Why?
| | Granulocyte Colony-Stimulating Factor | 2 | 2016 | 90 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2026 | 849 | 0.230 |
Why?
| | History, 21st Century | 2 | 2018 | 222 | 0.220 |
Why?
| | History, 20th Century | 2 | 2018 | 328 | 0.210 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2024 | 701 | 0.210 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2026 | 411 | 0.210 |
Why?
| | Endocrinology | 1 | 2025 | 77 | 0.210 |
Why?
| | Pluripotent Stem Cells | 2 | 2022 | 81 | 0.210 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2024 | 130 | 0.200 |
Why?
| | Ovarian Neoplasms | 1 | 2010 | 595 | 0.200 |
Why?
| | Hybridomas | 3 | 2020 | 233 | 0.200 |
Why?
| | Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.190 |
Why?
| | Protein Binding | 3 | 2021 | 2240 | 0.190 |
Why?
| | Lipodystrophy | 1 | 2023 | 12 | 0.190 |
Why?
| | Contrast Media | 1 | 2026 | 497 | 0.190 |
Why?
| | CD3 Complex | 2 | 2020 | 112 | 0.190 |
Why?
| | Drug Delivery Systems | 1 | 2026 | 381 | 0.180 |
Why?
| | Histocompatibility Antigens | 1 | 2021 | 102 | 0.170 |
Why?
| | Molecular Sequence Data | 3 | 2015 | 2883 | 0.170 |
Why?
| | Insulin, Regular, Human | 1 | 2020 | 47 | 0.160 |
Why?
| | Rhizotomy | 1 | 2000 | 5 | 0.160 |
Why?
| | Polyethylene Glycols | 2 | 2016 | 649 | 0.160 |
Why?
| | Virus Diseases | 2 | 2015 | 216 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2181 | 0.160 |
Why?
| | Brachial Plexus | 1 | 2000 | 34 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1062 | 0.150 |
Why?
| | Retroviridae | 1 | 2020 | 100 | 0.150 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2021 | 202 | 0.150 |
Why?
| | Muscle Spasticity | 1 | 2000 | 63 | 0.150 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 9 | 0.150 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2019 | 15 | 0.150 |
Why?
| | Arm | 1 | 2000 | 110 | 0.150 |
Why?
| | Case-Control Studies | 3 | 2022 | 3634 | 0.150 |
Why?
| | Immunoassay | 1 | 2020 | 109 | 0.150 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 37 | 0.150 |
Why?
| | Stem Cells | 2 | 2021 | 630 | 0.150 |
Why?
| | Glucagon-Like Peptides | 1 | 2020 | 71 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 534 | 0.140 |
Why?
| | Genotype | 2 | 2015 | 1857 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2026 | 11793 | 0.140 |
Why?
| | Aged | 6 | 2026 | 26215 | 0.140 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2019 | 177 | 0.140 |
Why?
| | HLA-DRB1 Chains | 1 | 2019 | 110 | 0.140 |
Why?
| | Models, Molecular | 2 | 2015 | 1599 | 0.140 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 138 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4329 | 0.140 |
Why?
| | Transglutaminases | 2 | 2016 | 159 | 0.130 |
Why?
| | Community Health Services | 1 | 2019 | 231 | 0.130 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 177 | 0.130 |
Why?
| | Genetic Heterogeneity | 1 | 2017 | 66 | 0.130 |
Why?
| | Treatment Failure | 1 | 2018 | 360 | 0.130 |
Why?
| | Tissue Donors | 2 | 2021 | 420 | 0.130 |
Why?
| | Amino Acid Sequence | 3 | 2017 | 2131 | 0.120 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 27 | 0.120 |
Why?
| | Radioimmunoassay | 1 | 2016 | 165 | 0.120 |
Why?
| | Antibodies, Viral | 1 | 2021 | 674 | 0.120 |
Why?
| | Immune Tolerance | 2 | 2026 | 385 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 976 | 0.120 |
Why?
| | Luminescence | 1 | 2016 | 37 | 0.120 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2191 | 0.120 |
Why?
| | Mutation | 3 | 2015 | 4090 | 0.120 |
Why?
| | Luminescent Measurements | 1 | 2016 | 75 | 0.110 |
Why?
| | Dideoxynucleosides | 1 | 2015 | 24 | 0.110 |
Why?
| | Administration, Oral | 1 | 2018 | 867 | 0.110 |
Why?
| | Donor Selection | 1 | 2016 | 79 | 0.110 |
Why?
| | Immunologic Memory | 1 | 2017 | 368 | 0.110 |
Why?
| | Sensitivity and Specificity | 4 | 2026 | 2000 | 0.110 |
Why?
| | Antigen-Presenting Cells | 1 | 2015 | 159 | 0.110 |
Why?
| | Monocytes | 2 | 2016 | 539 | 0.110 |
Why?
| | Abatacept | 1 | 2014 | 56 | 0.110 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 387 | 0.100 |
Why?
| | Vitamin B Complex | 1 | 2014 | 39 | 0.100 |
Why?
| | Early Medical Intervention | 1 | 2014 | 63 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2015 | 175 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 100 | 0.100 |
Why?
| | Multifactorial Inheritance | 1 | 2015 | 209 | 0.100 |
Why?
| | B-Lymphocytes | 1 | 2019 | 872 | 0.100 |
Why?
| | Niacinamide | 1 | 2014 | 104 | 0.100 |
Why?
| | Chromogranin A | 1 | 2013 | 43 | 0.100 |
Why?
| | CD4 Antigens | 1 | 2013 | 137 | 0.100 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 46 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 310 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 251 | 0.090 |
Why?
| | Immunoconjugates | 1 | 2014 | 138 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2014 | 147 | 0.090 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 104 | 0.090 |
Why?
| | Colorado | 2 | 2021 | 4556 | 0.090 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 172 | 0.090 |
Why?
| | Polymorphism, Genetic | 1 | 2015 | 615 | 0.090 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 219 | 0.090 |
Why?
| | Primary Prevention | 1 | 2014 | 222 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 1101 | 0.090 |
Why?
| | Celiac Disease | 1 | 2016 | 311 | 0.090 |
Why?
| | Incidence | 1 | 2019 | 2933 | 0.090 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 189 | 0.090 |
Why?
| | Pancreas, Artificial | 1 | 2013 | 97 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2018 | 712 | 0.090 |
Why?
| | Alum Compounds | 1 | 2011 | 26 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2018 | 852 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 346 | 0.080 |
Why?
| | Cytokines | 2 | 2017 | 2069 | 0.080 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 111 | 0.080 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 563 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2014 | 500 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2011 | 135 | 0.080 |
Why?
| | Thyroglobulin | 1 | 2010 | 29 | 0.080 |
Why?
| | Whole Body Imaging | 1 | 2010 | 29 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2010 | 116 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1512 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 94 | 0.070 |
Why?
| | Iodine Radioisotopes | 1 | 2010 | 138 | 0.070 |
Why?
| | Self Tolerance | 1 | 2009 | 26 | 0.070 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 74 | 0.070 |
Why?
| | Organ Specificity | 1 | 2010 | 309 | 0.070 |
Why?
| | Prospective Studies | 4 | 2026 | 8075 | 0.070 |
Why?
| | Hysterectomy | 1 | 2010 | 138 | 0.070 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 31 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 193 | 0.070 |
Why?
| | Mice, Inbred BALB C | 1 | 2011 | 1261 | 0.070 |
Why?
| | Interleukin-2 | 1 | 2010 | 440 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 381 | 0.070 |
Why?
| | Retrospective Studies | 1 | 2026 | 17325 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1751 | 0.070 |
Why?
| | Vaccines | 1 | 2011 | 389 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2601 | 0.060 |
Why?
| | Microbubbles | 1 | 2026 | 53 | 0.060 |
Why?
| | Histocompatibility Testing | 2 | 2017 | 123 | 0.060 |
Why?
| | Area Under Curve | 2 | 2016 | 332 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2019 | 574 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 5992 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 172 | 0.050 |
Why?
| | Risk Assessment | 1 | 2014 | 3752 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2026 | 361 | 0.050 |
Why?
| | Perilipin-1 | 1 | 2023 | 16 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1764 | 0.050 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 13 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2022 | 2050 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4568 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 473 | 0.040 |
Why?
| | Ultrasonography | 1 | 2026 | 788 | 0.040 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 36 | 0.040 |
Why?
| | Psychology, Child | 1 | 1981 | 36 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1736 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 171 | 0.040 |
Why?
| | Neurologic Examination | 1 | 2000 | 132 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 129 | 0.040 |
Why?
| | HLA-B15 Antigen | 1 | 2019 | 12 | 0.040 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 94 | 0.040 |
Why?
| | Hand Strength | 1 | 2000 | 144 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2020 | 277 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2019 | 200 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2020 | 174 | 0.040 |
Why?
| | Hand | 1 | 2000 | 157 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1165 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2020 | 335 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2018 | 179 | 0.030 |
Why?
| | Psychotic Disorders | 1 | 1981 | 192 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2023 | 645 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 375 | 0.030 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2018 | 78 | 0.030 |
Why?
| | Gene Editing | 1 | 2018 | 89 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 489 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 6032 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 376 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2018 | 189 | 0.030 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 265 | 0.030 |
Why?
| | Receptors, CXCR3 | 1 | 2016 | 17 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2016 | 34 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 741 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2016 | 77 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 519 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2016 | 209 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2016 | 118 | 0.030 |
Why?
| | Skin | 1 | 2019 | 754 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 420 | 0.030 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 57 | 0.030 |
Why?
| | Colesevelam Hydrochloride | 1 | 2013 | 6 | 0.030 |
Why?
| | Gastrins | 1 | 2013 | 8 | 0.030 |
Why?
| | Chromatography, Gel | 1 | 2014 | 130 | 0.030 |
Why?
| | Allylamine | 1 | 2013 | 6 | 0.030 |
Why?
| | Dimerization | 1 | 2014 | 189 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2014 | 318 | 0.030 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2013 | 11 | 0.030 |
Why?
| | Bromocriptine | 1 | 2013 | 31 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2874 | 0.020 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2013 | 29 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2014 | 87 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2021 | 4151 | 0.020 |
Why?
| | Risk | 1 | 2016 | 923 | 0.020 |
Why?
| | Overweight | 1 | 2018 | 614 | 0.020 |
Why?
| | Sulfonylurea Compounds | 1 | 2013 | 51 | 0.020 |
Why?
| | Drug Combinations | 1 | 2014 | 396 | 0.020 |
Why?
| | Islet Amyloid Polypeptide | 1 | 2013 | 48 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1368 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 172 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2016 | 481 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2014 | 428 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 10917 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 193 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1330 | 0.020 |
Why?
| | Thiazolidinediones | 1 | 2013 | 143 | 0.020 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2013 | 149 | 0.020 |
Why?
| | Leptin | 1 | 2013 | 248 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2014 | 389 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 618 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2013 | 267 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3416 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Thymus Gland | 1 | 2011 | 312 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1068 | 0.020 |
Why?
| | Metformin | 1 | 2013 | 329 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3170 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1478 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2967 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2000 | 2977 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5223 | 0.010 |
Why?
| | Time Factors | 1 | 2016 | 7133 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 3118 | 0.010 |
Why?
| | Registries | 1 | 2013 | 2410 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5922 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2191 | 0.010 |
Why?
| | Language Development Disorders | 1 | 1981 | 41 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8346 | 0.010 |
Why?
| | Child Behavior Disorders | 1 | 1981 | 119 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 1981 | 131 | 0.010 |
Why?
| | Family | 1 | 1981 | 685 | 0.010 |
Why?
| | United States | 1 | 2013 | 16123 | 0.010 |
Why?
| | Communication | 1 | 1981 | 977 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|